Financial Performance - Q2 2025 - Net sales reached $175 million, a 2% organic growth compared to $172 million in Q2 2024[17] - Adjusted EBITDA was $17 million, representing a 10% margin, compared to $27 million in Q2 2024[17] - Adjusted EPS was $0.17, compared to $0.34 in Q2 2024[17] Segment Performance - Specialty Nutrition Systems net sales grew to $103 million, a 5% organic growth, compared to $98 million in Q2 2024[20] - Specialty Nutrition Systems operating profit was $18 million, representing an 18% margin, compared to $22 million in Q2 2024[21] - Pain Management & Recovery net sales grew to $61 million, a 34% organic growth, compared to $59 million in Q2 2024[26] - Pain Management & Recovery operating profit increased to $2 million, compared to $0 million in Q2 2024[27] Financial Position - Cash decreased to $90 million as of June 30, 2025, compared to $108 million as of December 31, 2024[30] - Net debt decreased to $15 million as of June 30, 2025, compared to $27 million as of December 31, 2024[30] - Net Debt / EBITDA ratio was approximately 02x as of June 30, 2025, compared to approximately 03x as of December 31, 2024[30] 2025 Outlook - Sales guidance reaffirmed at $665 million to $685 million[33] - Adjusted diluted EPS estimate maintained at $075 to $095[33]

ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2025 financial results."Building off our first quarter results, we delivered a strong second quarter anchored by continued healthy performance in our life-sustaining Specialty Nutrition Systems segment along with continued progress in our opioid-sparing Pain Management & Recovery segment," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Our overall execution this quarter was ...

Q1 2025 Financial Performance - Net sales increased to $168 million in Q1 2025 from $166 million in Q1 2024, representing a 2.8% organic growth[19] - Adjusted EPS grew by 18% from $0.22 in Q1 2024 to $0.26 in Q1 2025[19] - The company generated $19 million of free cash flow during the quarter[22] - Net debt decreased to $10 million as of March 31, 2025, compared to $27 million as of December 31, 2024[21] Segment Performance - Specialty Nutrition Systems net sales increased to $101 million in Q1 2025 from $95 million in Q1 2024, reflecting a 9.4% organic growth[27] - Specialty Nutrition Systems operating profit increased by 37% from $15 million in Q1 2024 to $21 million in Q1 2025[29] - Pain Management & Recovery segment net sales remained stable at $56 million in Q1 2025, showing a 1.1% organic growth[33] - Pain Management & Recovery segment operating profit improved from -$2 million in Q1 2024 to $0 million in Q1 2025[34] 2025 Outlook - The company maintains its sales estimate of $665 million to $685 million[44] - The company lowered its adjusted diluted EPS estimate to $0.75 to $0.95, primarily due to tariff impacts[45]